Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating ...

Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before ...

SG Americas Securities LLC cut its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) by 28.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 12,518 shares of the company ...

QIAGEN N.V.’s QGEN fourth-quarter 2024 adjusted earnings per share (EPS) were 61 cents, the same at the constant exchange ...

The board of directors of Franklin Lakes-based, global medical technology company BD, has unanimously authorized BD management ...

Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.

Healthcare is undergoing a seismic transformation. The old paradigm of brick-and-mortar hospitals is giving way to a new ...

From chatbots supporting patients to AI diagnostic tools, artificial intelligence is reshaping healthcare delivery, as evidenced at the IMAGINE AI event.

Consultation launches on the biggest shake-up of NICE's HealthTech programme to date. More innovative healthcare technologies could soon be adopted by the NHS under reforms proposed today by NICE.

Learn more about whether Enovis Corporation or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.